Broadcom (AVGO) vs. Eli Lilly (LLY)
This page compares Broadcom (AVGO) with Eli Lilly (LLY) using performance and risk, profitability, financial strength, growth, dividends, and valuation metrics.
Company Profile
Broadcom (AVGO) is classified in the Information Technology sector (Semiconductors & Semiconductor Equipment), whereas Eli Lilly (LLY) belongs to Health Care (Pharmaceuticals, Biotechnology & Life Sciences) — their GICS classifications point to very different parts of the market.
| Symbol | AVGO | LLY |
|---|---|---|
| Name | Broadcom Inc. | Eli Lilly and Company |
| Country/Region | United States | United States |
| GICS Sector | Information Technology | Health Care |
| GICS Industry Group | Semiconductors & Semiconductor Equipment | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Semiconductors & Semiconductor Equipment | Pharmaceuticals |
| GICS Sub-Industry | Semiconductors | Pharmaceuticals |
| Market Capitalization | 1,865.73 billion USD | 1,020.76 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | NYSE |
| Listing Date | August 6, 2009 | June 1, 1972 |
| Security Type | Common Stock | Common Stock |
Valuation
Price-to-Earnings Ratio (TTM)
Both Broadcom (AVGO) at 65.36 and Eli Lilly (LLY) at 40.65 post Price-to-Earnings Ratio (TTM) near the typical industry midpoint — neither company stands out strongly from peers on trailing earnings multiple.
AVGO
Semiconductors & Semiconductor Equipment industry group
65.36
- Max
- 249.03
- Q3
- 128.05
- Median
- 64.96
- Q1
- 44.86
- Min
- 6.63
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
40.65
- Max
- 86.12
- Q3
- 44.09
- Median
- 25.14
- Q1
- 14.77
- Min
- 1.59
Price-to-Sales Ratio (TTM)
Eli Lilly (LLY) at 14.13 is priced about in line with its industry on Price-to-Sales Ratio (TTM), while Broadcom (AVGO) at 24.72 sits in the pricier quartile — AVGO costs more per dollar of sales.
AVGO
Semiconductors & Semiconductor Equipment industry group
24.72
- Max
- 37.59
- Q3
- 20.61
- Median
- 9.67
- Q1
- 4.25
- Min
- 0.01
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
14.13
- Max
- 41.86
- Q3
- 22.86
- Median
- 6.80
- Q1
- 3.35
- Min
- 0.01
Price-to-Book Ratio (MRQ)
Both look rich against book: Broadcom (AVGO) at 21.23 sits in the upper Price-to-Book Ratio (MRQ) quartile, and Eli Lilly (LLY) at 32.78 prices even higher, above its industry range.
AVGO
Semiconductors & Semiconductor Equipment industry group
21.23
- Max
- 25.80
- Q3
- 14.33
- Median
- 7.69
- Q1
- 3.77
- Min
- 0.22
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
32.78
- Max
- 12.97
- Q3
- 6.18
- Median
- 3.45
- Q1
- 1.62
- Min
- -4.60
Valuation at a Glance
| Symbol | AVGO | LLY |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 65.36 | 40.65 |
| Price-to-Sales Ratio (TTM) | 24.72 | 14.13 |
| Price-to-Book Ratio (MRQ) | 21.23 | 32.78 |
| Free Cash Flow Yield | 1.46% | 0.90% |
Profitability
Return on Equity (TTM)
Eli Lilly (LLY) leads with Return on Equity (TTM) of 107.46%, above its industry benchmark range, while Broadcom (AVGO) at 37.28% also ranks strongly in the top quartile.
AVGO
Semiconductors & Semiconductor Equipment industry group
37.28%
- Max
- 39.82%
- Q3
- 17.52%
- Median
- 6.57%
- Q1
- -4.94%
- Min
- -35.15%
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
107.46%
- Max
- 100.65%
- Q3
- 3.39%
- Median
- -31.16%
- Q1
- -61.60%
- Min
- -158.89%
Net Profit Margin (TTM)
Eli Lilly (LLY) at 34.99% keeps the most of each sales dollar — above its industry’s Net Profit Margin (TTM) range — and Broadcom (AVGO) at 38.85% also retains a top-quartile share.
AVGO
Semiconductors & Semiconductor Equipment industry group
38.85%
- Max
- 57.72%
- Q3
- 20.98%
- Median
- 7.10%
- Q1
- -3.84%
- Min
- -32.92%
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
34.99%
- Max
- 13.81%
- Q3
- 4.07%
- Median
- 0.00%
- Q1
- -3.07%
- Min
- -13.58%
Operating Profit Margin (TTM)
Both Broadcom (AVGO) at 48.99% and Eli Lilly (LLY) at 49.39% squeeze more operating profit from each sales dollar than most peers, ranking in the top Operating Profit Margin (TTM) quartile of their industries.
AVGO
Semiconductors & Semiconductor Equipment industry group
48.99%
- Max
- 65.60%
- Q3
- 21.58%
- Median
- 9.68%
- Q1
- -8.51%
- Min
- -46.64%
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
49.39%
- Max
- 100.30%
- Q3
- 4.94%
- Median
- 0.00%
- Q1
- -133.46%
- Min
- -337.81%
Profitability at a Glance
| Symbol | AVGO | LLY |
|---|---|---|
| Return on Equity (TTM) | 37.28% | 107.46% |
| Return on Assets (TTM) | 12.12% | 20.74% |
| Net Profit Margin (TTM) | 38.85% | 34.99% |
| Operating Profit Margin (TTM) | 48.99% | 49.39% |
| Gross Profit Margin (TTM) | 76.28% | 82.83% |
Growth
Revenue Growth
Revenue Growth at a Glance
| Symbol | AVGO | LLY |
|---|---|---|
| 1-Year Revenue Growth | 23.87% | 44.70% |
| 3-Year Revenue CAGR | 24.38% | 31.69% |
EPS Growth
EPS Growth at a Glance
| Symbol | AVGO | LLY |
|---|---|---|
| 1-Year EPS Growth | 287.80% | 95.99% |
| 3-Year EPS CAGR | 21.60% | 51.71% |
Financial Strength
Current Ratio (MRQ)
Both Broadcom (AVGO) at 2.24 and Eli Lilly (LLY) at 1.50 run Current Ratio (MRQ) in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.
AVGO
Semiconductors & Semiconductor Equipment industry group
2.24
- Max
- 11.30
- Q3
- 6.01
- Median
- 3.26
- Q1
- 2.37
- Min
- 0.51
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.50
- Max
- 24.81
- Q3
- 11.75
- Median
- 5.47
- Q1
- 2.69
- Min
- 0.23
Debt-to-Equity Ratio (MRQ)
Both Broadcom (AVGO) at 0.74 and Eli Lilly (LLY) at 1.39 run Debt-to-Equity Ratio (MRQ) in the higher-leverage quartile of industry peers, indicating more debt relative to equity than typical competitors.
AVGO
Semiconductors & Semiconductor Equipment industry group
0.74
- Max
- 1.53
- Q3
- 0.64
- Median
- 0.21
- Q1
- 0.04
- Min
- 0.00
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.39
- Max
- 1.60
- Q3
- 0.69
- Median
- 0.16
- Q1
- 0.02
- Min
- 0.00
Financial Strength at a Glance
| Symbol | AVGO | LLY |
|---|---|---|
| Current Ratio (MRQ) | 2.24 | 1.50 |
| Debt-to-Equity Ratio (MRQ) | 0.74 | 1.39 |
| Net Debt / EBITDA | 1.08 | 1.05 |
Dividends
Dividend Yield (TTM)
Broadcom (AVGO) at 0.66% reports Dividend Yield (TTM) in the top quartile of industry peers, ahead of Eli Lilly (LLY) at 0.60%, which sits around the industry mid-range.
AVGO
Semiconductors & Semiconductor Equipment industry group
0.66%
- Max
- 1.15%
- Q3
- 0.46%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.60%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Both Broadcom (AVGO) at 41.26% and Eli Lilly (LLY) at 22.13% post Dividend Payout Ratio (TTM) outside their industries’ typical mid-range — either leaning toward more retention or more distribution than the industry median.
AVGO
Semiconductors & Semiconductor Equipment industry group
41.26%
- Max
- 41.26%
- Q3
- 19.10%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
22.13%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividends at a Glance
| Symbol | AVGO | LLY |
|---|---|---|
| Dividend Yield (TTM) | 0.66% | 0.60% |
| Dividend Payout Ratio (TTM) | 41.26% | 22.13% |
Performance & Risk
Broadcom (AVGO) has an aggressive beta of 1.45, indicating higher sensitivity to broad-market moves, while Eli Lilly (LLY) is defensive at 0.51 and tends to be less market-sensitive — they sit on opposite ends of the beta spectrum.
Performance & Risk at a Glance
| Symbol | AVGO | LLY |
|---|---|---|
| 1-Year Return | 61.91% | 50.32% |
| 1-Year Volatility | 45.39% | 38.24% |
| Beta | 1.45 | 0.51 |
| 3-Month Avg. Volume | 25.23M | 3.15M |